Dental Bone Graft Substitutes Market Size, Share & Trends Analysis | China | 2025-2031 | Includes: Dental Barrier Membranes, Antimicrobial Periodontal Treatment, and 2 more

The Chinese dental bone graft substitute (DBGS) and other biomaterials market was valued at nearly $264 million in 2024. It is expected to grow at a compound annual growth rate of 14.7% to reach almost $690 million by 2031.

This report covers dental bone graft substitutes, dental barrier membranes, local antimicrobial periodontal treatments, and dental soft tissue wound care. Together, these categories are referred to as the dental biomaterials market. The study quantifies unit sales, average selling prices (ASPs), market size, growth rates, and company shares. It also analyzes market drivers and limiters, recent mergers and acquisitions, technology and practice trends, and competitive strategies. The report includes historical data to 2021 and forecasts to 2031.

China is one of the fastest growing markets for dental biomaterials. Growth is supported by higher dental implant procedure volumes, rising consumer awareness of regenerative dentistry, and increased acceptance of allograft and xenograft materials. While synthetic materials remain relevant, the allograft and xenograft segments are expanding faster, which is reshaping product mix and pricing dynamics.

Market Overview

The Chinese dental biomaterials market is scaling quickly as implant dentistry becomes more common in private clinics and hospital departments. A growing middle class, wider access to dental care, and investment in advanced restorative procedures are raising the demand for predictable bone and soft tissue regeneration.

The strongest growth within biomaterials is in dental bone graft substitutes. In particular, allograft and xenograft segments are expanding faster than synthetic materials. This change reflects growing clinical confidence in biologic grafts and improved patient acceptance. The shift also aligns with the introduction of local suppliers that meet national regulatory requirements, which helps with availability and pricing.

Barrier membranes are also gaining traction as clinicians standardize guided bone regeneration and guided tissue regeneration protocols. As training expands, more providers are pairing grafts with resorbable and non-resorbable membranes to improve outcomes and reduce reentry procedures. Antimicrobial periodontal treatments and soft tissue wound care products round out the ecosystem by supporting infection control and healing.

Market growth remains sensitive to regulatory processes and pricing. CFDA requirements, clinic budgets, and out-of-pocket payment models influence what products are selected and when. Even so, the long-term outlook is positive due to an increasing number of implant cases, broader education, and the normalization of allograft and xenograft use in everyday practice.

Market Drivers

Growth of Dental Implant Procedures

Most DBGS procedures occur with implant cases. As the number of implants rises, the pool of patients who can benefit from grafting grows as well. Not every implant requires a graft, but many sites have defects that need volume or contour improvement. This link between implant placement and bone grafting supports steady demand for DBGS materials.

Geistlich's Global Brand Recognition

Geistlich is a recognized leader in regenerative materials. Its reputation and long clinical history help reassure dentists and patients in China. This trust encourages adoption of xenograft products in cases where clinicians seek consistent handling and predictable outcomes. Over time, familiarity with Geistlich's portfolio has supported a wider use of xenografts in place of some autogenous options.

Consumer Acceptance of Allograft Products

Acceptance of allograft materials has improved due to education, peer-reviewed publications, and conference activity. As perception shifts, the market has seen the formation of regional tissue banks and a clearer supply pathway. This has reduced reliance on autogenous bone in select indications and opened the door for more standardized regenerative protocols.

Training and Clinical Education

Education drives utilization. Hands-on courses and study clubs teach clinicians how to select materials, shape grafts, and place membranes. As providers gain experience, they are more likely to integrate grafting into implant plans and periodontal treatment paths. Training supports higher success rates and repeat adoption.

Broader Product Choice and Portfolio Bundling

Clinics prefer streamlined purchasing. Suppliers that offer grafts, membranes, antimicrobial inserts, and wound care in one portfolio can reduce ordering complexity. Bundled offerings also support consistent clinical workflows. As portfolios expand, adoption of membranes and related products tends to rise alongside DBGS materials.

Market Limiters

Improvements in Dental Health

Better oral hygiene and preventive care reduce the need for complex restorative work over time. This trend can slow the growth rate of procedures that use DBGS and membranes, even as the older population grows.

Costs and the Public Health System

Major dental procedures that use biomaterials are generally paid out of pocket if patients do not carry supplemental coverage. Price sensitivity can delay treatment or steer choices to lower cost materials. This effect is stronger outside large urban centers.

Strict Regulatory Environment

Products sold in China are subject to CFDA requirements. Foreign manufacturers often need to complete local clinical studies and navigate a detailed registration process. These steps can delay product launches and limit the number of available brands in select categories. As a result, market entry costs are higher and timelines are longer.

Risk of Disease Transmission

Some practitioners remain cautious about human or animal-derived materials. Reports about tissue sourcing or infection can influence clinician and patient choices, even when unrelated to dental use. Persistent caution can shift usage toward synthetic or autogenous options in some clinics.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, market forecasts, growth rates, units sold, and ASPs.
• Qualitative coverage: Growth trends, market limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles, product portfolios, disruptive technologies, and disease overviews that shape demand.
• Time frame: Base year 2024, forecasts to 2031, historical data from 2021 to 2023.
• Data sources: Primary interviews with industry leaders, government physician and regulatory data, hospital and private clinic data, import and export records, and the iData Research internal database.
• Method note: Revenue is modeled as units multiplied by ASP. Models are validated with procedure volumes, utilization inputs, and distributor feedback across care settings.

Care settings include public hospitals, private hospitals, academic dental centers, and private dental clinics.

Markets Covered and Segmentation

Dental Bone Graft Substitutes (DBGS)

• By type: Allografts, xenografts, synthetics.

Dental Barrier Membranes

• By type: Resorbable, non-resorbable.
• By material: Allografts, xenografts, synthetics.

Antimicrobial Periodontal Treatment

Local antimicrobial therapies used to reduce bacterial load and support healing in periodontal pockets.

Dental Soft Tissue Wound Care

• By type: Plug, tape, foam.

This segment is analyzed at a unit level only.

Each subcategory includes market values, unit volumes, ASPs, and forecast growth, along with competitive context where applicable.

Competitive Analysis

Geistlich led the expanding xenograft market in 2024. The company's global reputation and documented clinical track record support strong clinician trust. By establishing a local affiliate in China, Geistlich addressed cultural and communication barriers, enhanced service levels, and increased brand awareness. This local presence, combined with ongoing education, positions Geistlich to keep its leadership as xenograft usage grows.

Shanxi OsteoRad held a leading position in the allograft category after gaining CFDA approval for its products. Due to strict regulation, the number of allograft suppliers in China remains limited. Many international allograft brands have not yet entered the market, which strengthens the competitive stance of approved domestic providers. Shanxi OsteoRad ranked second in the overall DBGS and biomaterials market in 2024 due to this supply position and category focus.

Dexcel Pharma ranked third overall in 2024, supported by leadership in local antimicrobial periodontal treatment. Its PerioChip(R) product contains 2.5 mg chlorhexidine digluconate in a small biodegradable insert designed for placement into periodontal pockets. Broad clinical familiarity with chlorhexidine and established handling protocols support stable usage across Asia Pacific, including China.

Competition is active across price tiers and material types. International brands emphasize clinical heritage and training, while domestic firms focus on regulatory alignment, localized support, and cost control. This structure supports continued growth but also raises the bar for quality systems, evidence, and post-market engagement.

Technology and Practice Trends

• Faster growth in allograft and xenograft: These categories are gaining share ahead of synthetics due to perceived biological performance and handling.
• Standardization of GBR and GTR: More clinicians pair grafts with resorbable or non-resorbable membranes to improve stability and shape maintenance.
• Focus on safety and processing: Sterilization, sourcing transparency, and documentation are central to product selection. Clear labeling and training reduce hesitation.
• Portfolio bundling: Suppliers promote integrated kits that include grafts, membranes, and wound care items to streamline case planning and purchasing.
• Chair-time efficiency: Products that handle well and reduce surgical time support adoption, especially in high-volume clinics.
• Education and mentorship: Study clubs and live courses accelerate the spread of predictable, stepwise regenerative protocols beyond major cities.

Geography

This edition covers China.

Why This Report

Where are the largest and fastest-growing opportunities within China's dental biomaterials market.

How will the mix shift toward allograft and xenograft affect pricing, training, and supplier share.

Which barrier membranes and periodontal antimicrobials are expanding most quickly and why.

How do CFDA requirements and clinical study needs affect market entry and product timelines.

What are the key risks to growth, including disease transmission concerns and out-of-pocket costs.

How should suppliers bundle portfolios to improve cross-selling and simplify clinic workflows.

What education and service models help clinics adopt predictable GBR and GTR protocols.

How can commercial teams plan for regional differences in price sensitivity and product mix.

The China Dental Bone Graft Substitute and Other Biomaterials Market Report from iData Research answers these questions with procedure-aware models, pricing detail, and company share analysis.

Use it to quantify demand by category, plan product launches, set pricing and contracting targets, and align training and support with the fastest growing segments.